Gilead Reports Phase 3 Trial Results in Patients with Coronvirus | Financial Buzz

Gilead Reports Phase 3 Trial Results in Patients with Coronvirus

Gilead Sciences, Inc. (NASDAQ: GILD) reported topline results from its Phase 3 SIMPLE trials in patients with COVID-19 pneumonia.  The study evaluated patients on 5-day and 10-day courses of the antiviral remdesivir drug.  The 5-day treatment group was 65% likely to have clinical improvement by day 11 compared to those in the start of care group.  Improvement odds in clinical status in the 10-day treatment course of remdesivir versus standard of care were favorable. 

“Our understanding of the spectrum of SARS-CoV-2 infection severity and presentations of COVID-19 continues to evolve,” said Francisco Marty, MD, an infectious diseases physician at Brigham and Women’s Hospital, and associate professor of medicine at Harvard Medical School. “These study results offer additional encouraging data for remdesivir, showing that if we can intervene earlier in the disease process with a 5-day treatment course, we can significantly improve clinical outcomes for these patients.”

“We now have three randomized, controlled clinical trials demonstrating that remdesivir improved clinical outcomes by several different measures. Today’s results showed that when treating moderate disease, a 5-day course of remdesivir led to greater clinical improvement than standard of care, adding further evidence of remdesivir’s benefit to previously released study results. The National Institute of Allergy and Infectious Diseases’ placebo-controlled study showed that remdesivir enabled more rapid recovery and that earlier treatment improved clinical outcomes. Our SIMPLE-Severe study showed that when treating patients with severe disease, 5 days of remdesivir led to similar clinical improvements as a 10-day course,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. “The additional data we have in hand today will further guide our research efforts, including evaluating treatment earlier in the course of disease, combination studies with other therapies for the most critically ill patients, pediatric studies and the development of alternate formulations.”